Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
aTyr Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was $21.47 Mil.
aTyr Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma EV-to-EBIT Related Terms
aTyr Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, aTyr Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's EV-to-EBIT falls into.
aTyr Pharma's current Enterprise Value is $-7.31 Mil.
aTyr Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a EV-to-EBIT of 0.10 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #19 out of 372 companies in the Biotechnology industry, placing it in the top 5.1%.
Is aTyr Pharma's EV-to-EBIT too high?
aTyr Pharma's current EV-to-EBIT is 0.10. The Biotechnology industry median EV-to-EBIT is 13.32. aTyr Pharma's value of 0.10 is 99.2% below this industry median. Based on the distribution chart, aTyr Pharma ranks #19 out of 372 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's EV-to-EBIT compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #19 out of 372 companies for EV-to-EBIT. This places aTyr Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.32. aTyr Pharma's value of 0.10 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.32, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current EV-to-EBIT of 0.10 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current EV-to-EBIT is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Fairly Valued. The stock's GF Value™ is $0.45, compared to a current price of $0.49 — trading 8.1% above its estimated fair value. The current EV-to-EBIT is 0.10 and 99.2% below the Biotechnology industry median of 13.32. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current EV-to-EBIT is 0.10 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.49 is trading 8.1% above its estimated GF Value™ of $0.45.
GuruFocus considers aTyr Pharma to be Fairly Valued.
Key valuation signals for ATYR:
EV-to-EBIT: 0.10
GF Value™: $0.45 vs. price of $0.49 (8.1% above fair value)
Industry Position: 99.2% below the Biotechnology median (#19 of 372)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
